Connect with us

Health

Cannabis reduces need for prescription drugs in MS patients

Published

on

Patients said cannabis offsets symptoms of MS and reduces their need for prescription medications

Multiple sclerosis (MS) patients who consume medical cannabis say they were able to reduce their prescription medicines to manage symptoms of the disease.

The majority of patients who consume medical cannabis report that it offsets symptoms of the disease and reduces their need for prescription medications, according to Survey data published in the journal Multiple Sclerosis and Related Disorders.

A team of investigators from the Yale University-Griffin Prevention Research Center surveyed 115 MS patients about their consumption of cannabis

Respondents were most likely to report that cannabis was effective in reducing symptoms of pain, insomnia, muscle cramps and spasms, as well as improving mood. 

Consistent with studies of other patient populations, “a significant proportion of respondents” reported having either “stopped or reduced” their use of prescription medications after finding cannabis to be more effective for symptom management. 

In particular, patients frequently reported reducing or ceasing their use of “opioids, benzodiazepines, muscle relaxers and other pain medications” – a finding that is also consistent with other studies

Authors concluded: “MCU [medical cannabis use] among PWMS [patients with MS] can lead to the reduction or discontinuation of several categories of prescription medications for symptoms of MS.”

In contrast to previous studies patients reporting the most benefits from cannabis tended to have a “milder form of MS with less disability”.  

They added: “This study confirms the benefit of cannabis in several common MS symptoms, extending these findings to show that benefit can be related to baseline severity of some symptoms.”

The medicinal use of cannabis is relatively common among people with MS, with an estimated one-in-five patients reporting current use. 

Cannabis derived oral extract drug, Sativex, is approved for the treatment of MS-related spasticity in a number of countries, including the UK. 

A recent US survey found that more than 40 percent of MS patients said they had used cannabis products in the past year, most likely to try them for help with chronic pain and sleep.

In a previous blog for Cannabis Health, Dr Anthony Ordman, senior clinical adviser and hon. clinical director at Integro Medical Cannabis Clinics said: “Over the years I have treated many MS patients in my clinics. Whilst they  generally receive excellent care for their MS, the secondary conditions such as chronic back pain can be neglected.

“Traditional pharmaceutical pain medicines often have unpleasant side effects such as brain fog and constipation and frequently stop working after a few weeks.

“Cannabis medicines can prove extremely helpful in the pain management of MS patients, because they reduce muscle spasm and inflammation.”

Full text of the study, “Patterns of medical cannabis use among patients diagnosed with multiple sclerosis,” appears in Multiple Sclerosis and Related Disorders

Sarah Sinclair is an award-winning freelance journalist covering health, drug policy and social affairs. She is one of the few UK reporters specialising in medical cannabis policy and as the former editor of Cannabis Health has covered developments in the European cannabis sector extensively, with a focus on patients and consumers. She continues to report on cannabis-related health and policy for Forbes, Cannabis Health and Business of Cannabis and has written for The i Paper, Byline Times, The Lead, Positive News, Leafie & others. Sarah has an NCTJ accreditation and an MA in Journalism from the University of Sunderland and has completed additional specialist training through the Medical Cannabis Clinicians Society in the UK. She has spoken at leading industry events such as Cannabis Europa.

Trending

Cannabis Health is a journalist-led news site. Any views expressed by interviewees or commentators do not reflect our own. All content on this site is intended for educational purposes, please seek professional medical advice if you are concerned about any of the issues raised.

Copyright © 2024 PP Intelligence Ltd.